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Embryonic stem (ES) cells are undifferentiated cells derived from embryos. ES cells possess the 
ability to proliferate and self-renew indefinitely and are able to differentiate to cells of three germ 
layer. However, they are technically difficult to handle and are ethically controversial. Yamanaka 
and his group succeeded in reprogramming somatic cells into pluripotent state by forced 
expression of transcription factors establishing induced pluripotent stem (iPS) cells. iPS cells are 
similar to ES cells but are advantageous as they can be a source of patient/model specific cells. 
Embryonal carcinoma (EC) cells are also similar to ES cells but are malignant. Given their 
pluripotent nature, iPS and EC cells serve as valuable alternatives to ES cells in the study of 
pluripotency and differentiation mechanisms such as neurogenesis.  
Neurogenesis is the process through which new nerve cells are generated from neural progenitor 
cells  and has been reported to persist even in the adult nervous system. As is the case with other 
development processes, neurogenesis is a complex process intricately modulated by mechanisms 
yet to be fully understood. Alterations in neurogenesis interferes with brain development, 
function resulting to cognitive deficits and neurological conditions.   
On the other hand, chromatin modulators such as histone deacetylase (Hdac) inhibitors have been 
used to improve reprogramming efficiency during iPS cell generation. Changes in histone 
acetylation status affect gene expression in turn controlling proliferation, differentiation and 
development. Hdacs consist of a number of isoforms that regulate cellular mechanisms differently. 
Hdac8 is an isoform expressed in the brain and in neuroblastoma and is associated with poor 
prognosis.    
This research aimed to 1) generate rat iPS cells using a non-viral plasmid vector and establish a 
protocol to differentiate them to neural lineage and 2) investigate the role of selectively inhibiting 
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Hdac8 on neurogenesis using retinoic acid treated P19 EC cells as a model. 
We successfully generated rat iPS cells (riPSC) and applied a multi-step protocol to differentiate 
riPSC to a neuronal lineage comprising of glutamatergic and dopaminergic neurons. 
Glutamatergic neurons were responsive to agonist stimulation. We also found a novel 
glycophenotypic difference in expression of epitopes that bind R-10G antibody, which reacts with 
human ES/iPS cells but not EC cells. riPSC clone highly reactive to R-10G formed teratomas 
consisting of derivatives of all three germ cell layers. On the other hand, low reactive clones 
resulted in tumor masses made up of undifferentiated cells. Conventionally used tumor rejection 
antigen (TRA)-1-81 epitope expression was comparable.  
In the second part of the study, we found HDAC8 inhibition suppressed proliferation, reducing 
size of P19 cell aggregates and 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4- 
disulfophenyl)-2H-tetrazolium (WST-8) reducing activity without inducing cell death. 
Anti-proliferative effect was characterized by upregulation of the cell cycle inhibitor p21 and 
mRNA expression. HDAC8 inhibition also resulted in downregulation of Sox2 protein level as 
well as Musashi-1 and repressor type bHLH factor, Hes5, mRNA expressions.  
The establishment of rat iPS cells and differentiation into neuronal lineage cells provides a model 
to help study neurogenesis processes as well as pharmacological and toxicological studies on 
neurons. Glygophenotypic difference with regard to R-10G found is potentially useful for rat iPS 
cell evaluation and to study the role of glycans in pluripotency and carcinogenesis in these cells. 
The findings of the second part of this thesis, uncover as well as suggest a role for HDAC8 
inhibition in proliferation and probably neurogenesis in pluripotent P19 cells.  
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PART 1: Generation of rat iPSC and differentiation to neuronal lineage cells.  
INTRODUCTION 
Yamanaka and his group opened a new era in stem cell science with the generation of induced 
pluripotent stem cells (iPSC) by the overexpression of transcription factors, octomer 3/4 (Oct3/4), 
SRY box-containg gene 2 (Sox2), c-Myc (myelocytomatosis cellular oncogene) and Kruppel-like 
factor 4 (Klf4) in mouse embryonic fibroblasts (MEF) (Takahashi and Yamanaka, 2006). Since 
then iPSC have been generated from human (Takahashi K.et al.,2007), monkey (Liu H. et al, 
2008), pig (Esteban et al. 2009), sheep (Bai et al. 2008) and rat (Li W. et al, 2009) among other 
mammalian species. iPSC are similar to embryonic stem cells (ESC) in regard to ability to 
self-renew and differentiate into a variety of cells. iPSC are derived from somatic cells hence 
they offer an alternative to ESC that are technically difficult to establish and make use of 
embryos raising ethical concerns. However, iPSC equivalency to ESC is still much debated.  
The rat has been useful as an animal model in many research fields (Jacob HJ. et al., 2010). Data 
from studies using rat models has formed a foundation for investigations into disease mechanism 
and therapeutic strategies. Despite authentic mouse ESC having been derived more than three 
decades ago (Evans and Kaufman, 1981), rat ESC were only recently established (Buehr M. et 
al.,2008; Li P. et al., 2008) making it possible to generate rats with genetic modifications (Tong C. 
et al. 2010). Several rat iPSC lines have been established (Liao J. et al., 2009; Li W. et al, 2009; 
Chang MY. et al., 2010; Liskovykh M. et al., 2011) and transgenic rats generated from rat iPSC 
(Jiang MG. et al.,2013). Hence, rat iPSC development is indeed a step forward. However, rat 
iPSC lines reported were generated via viral transduction of reprogramming factors which has 
disadvantages such as proviral integrations in resulting iPSC.   
Variation observed among iPSC of not only species of origin, but also reprogramming methods, 
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culture conditions and laboratory-specific variations remains a concern (Okita and Yamanaka 
2012). Issues regarding pluripotency, differentiation and tumorigenic propensity remain a 
challenge especially in employment of these cells for therapeutic purposes.    
Cell surface glycans are often referred to as cell signature and different cell types express 
different glycan patterns which vary during differentiation and various biological processes such 
as cancer (Sjoberg and Varki, 1993; Dodla MC. et al., 2011; Li M. et al., 2010). In this light, cell 
surface glycans are considered ideal targets for identifying and characterizing cellular phenotype. 
Cell surface glycans such as stage-specific embryonic antigens (SSEA)-3/4 and tumor rejection 
antigen (TRA)-1-60/81 are routinely used to evaluate pluripotency. However, these glycans are 
not unique to ESC and iPSC but are also expressed in embryonal carcinoma (EC) cells (Kannagi 
R. et al., 1983; Andrews PW. et al., 1984). Kawabe K. et al. generated a monoclonal antibody, 
R10-G, by using a human iPS cell line (Kawabe K. et al. 2013). The epitope binding R-10G was 
identified as a type of keratan sulfate similar to TRA-1-81 epitope but possessed unique 
properties. Moreover, this antibody only recognized human ES and iPS cells but not EC cells. 
Characterization of cell surface glycans in iPSC potentially offers a tool to elucidate changes that 
occur during reprogramming as well as the role of glycans in acquisition and maintenance of 
pluripotency and stemness.     
Aim: To generate rat iPSC (riPSC) using a non-viral plasmid vector introduced via 
electroporation and differentiate riPSC to neural lineage cells. 
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RESULTS 
Generation of riPSC and characterization. 
First, primary fibroblasts were prepared from skin biopsies of adult male Wistar rats and 
passaged twice at most prior to the reprogramming experiments. We introduced 8g of 
pCAG2LMKOSimO vector into 1.1×106 cells as described in the methods section. We then 
plated the fibroblasts on inactivated MEFs and cultured them in LIF and 400g G418 containing 
media. Colonies were visible from about day 7 post transfection. We picked a total of 11 colonies 
over a time span ranging from 14 to 20 days post transfection. The colonies were expanded 
during when we closely observed aspects such as colony morphology, growth rate, and presence 
of foci of increased growth as signs for similarity to ES cells. Figure 1 shows phase contrast 
images of source cells, adult rat fibroblasts and representative image of colonies.  
Figure 1. Source cells, adult rat fibroblasts and representative image of rat iPS cells 
(riPSC) cultured on mouse embryonic fibroblasts (MEFs).   
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ES cell colonies are known to have characteristic round bodies with sharp edges. Initially, our 
riPSC clone colonies seemed to be unsatisfactory in this light. This lead us to attempt the LIF+2i 
approach which Silvia et al. reported to induce transition of intermediate reprogramming states to 
ground state pluripotency in mouse iPS cells. 2i, CHIR99021 and PD0325901, are two small 
molecule inhibitors of the MAPK (mitogen activated protein kinase)/Erk (extracellular signal 
regulated kinases 1 and 2) pathway and GSK3 respectively. Indeed, this same approach 
successfully allowed the derivation of ES cell lines from rats which had been elusive for a long 
period of time (Buehr M et al, 2008; Li P et al, 2008). Addition of 2i to the culture system 
dramatically improved morphology of riPSC colonies. Hence, further culture was carried out in 
media containing LIF+2i. 
We next embarked on examining the ES cell like features and characterizing the riPSC clones. A 
useful tool for identifying pluripotency in initial phases of reprogramming is alkaline phosphatase 
(AP) staining (Brambrink, 2008). AP is a hydrolase enzyme that under alkaline conditions 
dephosphorylates nucleotides and proteins and elevated levels is associated with pluripotent 
phenotypes (Thomson and Marshall, 1998). riPSC clones were cultured on MEFs and stained for 
AP after 3 days. Figure 2 shows riPSC colonies stained for AP (reddish purple appearance) while 
rat fibroblasts, the source cells were unreactive (clear appearance) indicating riPSC were of a 
pluripotent nature. In the cause of propagating the colonies, we selected a three clones to carry 
downstream experiments namely riPSC#3, #6 and #11 as other clones showed poor propensity 
and could not be maintained in culture. 
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Next, we carried out immunocytochemical staining for ES cell marker, Nanog, surface marker 
and stage-specific embyronic antigen, SSEA1. riPSC were passaged and cultured for 5 days 
before fixation with 4% PFA and then immunoreacted with respective antibodies. Consistent with 
studies carried out on rat ES cells, the riPSC clones expressed Nanog (nuclear localized) and 
SSEA-1 (cell surface localized) (Figure3). Control experiments showed rAF were unreactive. 
Furthermore, Nanog and SSEA-1 expression were confirmed in riPSC clones after multiple 
passages (Figure 4.)  
Figure 2. Alkaline Phosphatase (AP) Staining. AP staining of adult rat fibroblasts, riPSC#6 
and riPSC#11.  
Figure 3. Characterization 
of riPSC. Nanog and 
SSEA-1 expression in 
riPSC#6 and riPCS#11 
were determined by 
immunocytochemistry.   
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Figure 4. Characterization of riPSC. Nanog and SSEA-1 expression in riPSC#6 and 
riPCS#11 respectively, were determined by immunocytochemistry after multiple passages.  
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Furthermore, we assessed expression of endogenous transcripts for pivotal pluripotency genes by 
RT-PCR. Figure 5 shows riPSC clones expressed these genes whose expression was undetected 
in rat fibroblast samples. Taken together, these data confirmed reprogramming had indeed taken 
place. 
The conversion of somatic cells into iPS cells during the reprogramming process is accompanied 
by epigenetic changes including demethylation of promoter and enhancer regions of pluripotency 
genes such as Oct3/4. We therefore examined the methylation status of the rat Oct3/4 promoter 
region (-1495 to 1290 bp) by bisulfite sequencing. Bisulfite sequencing involves the denaturing 
of genomic DNA followed by treatment of DNA with sodium bisulfite that results into 
conversion of unmethylated cytosine residues to uracil. Methylated cytosine residues remain 
unchanged. PCR amplication using primers specific to the region of interest converts uracil 
Figure 5. Characterization of riPSC. RT-PCR analysis of ES marker genes. riPSC express 
endogenous ES marker genes. Source cells (rAF) were used as negative control. GAPDH 
was used as loading control.  
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residues to thymine. PCR products are sequenced determining DNA methylation status.  
Our findings revealed a difference in the riPSC clones we had established. riPS#6 was relatively 
hypomethylated while riPS#11 showed a higher methylation status. This was unexpected given 
endogenous Oct3/4 transcripts had been detected in the cells. We decided to confirm Oct3/4 
protein expression though immunostaining. Cells were passaged and routinely cultured on MEFs 
for 5 days followed by fixation in 4%PFA and reaction with Oct3/4 antibody. As shown in figure 
7, there was no significant difference in Oct3/4 protein expression levels in the clones.  
Figure 6. Characterization of riPSC. Bisulfite sequencing of promoter region of rat Oct3/4.
Open circles represent unmethylated CpGs. Filled circles indicate methylated CpGs.  
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We also examined karyotypic status of riPSC clones after repeated passages. Metaphase spreads 
were prepared and 100 spreads were counted for each riPSC clone. riPS#6 had a majority (60%)  
of normal karyotype (2n=42) spread. Contrastingly, riPS#11 and riPS#3 had mostly aneuploidy 
spreads with an increase in the number of chromosomes of up to 64.   
Figure 7. Characterization of riPSC. Immunocytochemical analysis of Oct3/4 expression in 
riPSC#6 and riPSC#11. riPSC clones were homogenously labeled with antibodies against 
Oct3/4 (red). Nucleus was stained with DAPI (blue).  
Figure 8. Characterization of 
riPSC. Representative 
metaphase spreads of 
riPSC#6 and riPSC#11. riPSC 
showed majority normal 
(2N=42) chromosome 
content. riPSC#11 spreads 
were mostly abnormal with 
up to 2N=64 chromosome 
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Primary somatic cells in their native nature have a limited capacity to be cultured and can only be 
passaged for a limited duration before they become senescent; a concept first propose by Leonard 
Hayflick about five decades ago (Shaw JW, Wright WE 2000). iPS cells gain the ability to be 
expanded and maintained in culture indefinitely making them similar to ES cells in this light. We 
were able to maintain riPSC in culture for over 15 passages without notable change in 
morphological appearance.  
R-10G reactivity 
To characterize the riPSC clones further, we tested the binding of R-10G antibody to the cells. 
riPSC were routinely cultured on MEFs for 3-5 days and fixed with 4% PFA for immunostaining 
experiments. Unexpectedly, R-10G binding appeared to be differential in the riPSC. Initially, we 
used the conventional immunostaining protocol that involved fixation, permeablization, blocking 
and antibody reaction. As in Figure 9, we were unable to determine clear localization and the 
immunofluorescence results were unsatisfactory. Nevertheless, riPSC#11 was only lowly reactive 
to the antibody. 
Figure 9. R-10G 
reactivity. riPSC were 
fixed, permeabilized 
and immunoreacted 
with R-10G (green) 
and Nanog (red) 
antibodies. Upper 
panel shows riPSC#6, 
lower panel shows 
riPSC#11.   
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Since the epitope recognized by R-10G is localized on the cell surface, we decided not to treat the 
cells with a surfactant, omitting the permeabilization step hence ensuring the cell surface 
remained intact. With this we successfully obtained clearer images that confirmed riPS#6 showed 
higher reactivity to R-10G antibody in comparison to other clones (Figure 10). 
Kawabe et al. identified the antigen carrying the R-10G epitope as the transmembrane protein 
podocalyxin (Kawabe et al 2013). Podocalyxin consists of a cytoplasmic domain and an 
extracellular domain which is heavily glycosylated (Sassett et al. 2000). Podocalyxin also acts as 
a carrier protein to the TRA-1-60 and TRA-1-81 epitopes, both of which are conventionally used 
ES/iPS cell marker antibodies (Schopperle and DeWolf 2007).  
Our observations in difference in riPSC clone reactivity to R-10G might have been as a result of 
(1) differences in R-10G binding epitope expression or (2) differences in carrier protein 
expression levels. To test these possibilities, we performed immunofluoresence staining using 
R-10G and TRA-1-81. Cells were cultured routinely on 6cm tissue culture dishes for 4 days and 
Figure 10. R-10G reactivity. riPSC#6 were fixed in 4% PFA and reacted with R-10G without 
permeabilization. Left panel: R-10G (green). Right panel: phase contrast image.  
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reacted with respective primary and secondary antibodies. Nuclei were stained with DAPI. 
Images were acquired using a fluorescent microscope.  
Figure 11. R-10G and TRA-1-81 binding. Upper panel: riPSC#6, Lower panel: riPSC#11 
R-10G (green) TRA-1-81 (red) DAPI (blue). Quantification of fluorescence intensity. Results 
were normalized against DAPI. Results are means ?S.D. of 81 random fields from three 
independent experiments.  
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Fluorescence intensity was quantitated using the KEYENCE Hybrid Cell Count BZ-H2C 
software. Fluorescence intensity for green (R-10G) and red (TRA-1-81) were normalized against 
blue (DAPI). Results are shown in Figure 11 above. TRA-1-81 bound with riPSC#6 and 
riPSC#11 in a similar fashion and fluorescence intensity was comparable. Consistent with 
previous observations, R-10G staining intensity was approximately three times lower in 
riPSC#11 in comparison with riPSC#6. 
In vitro differentiation 
R-10G did not bind, 2102Ep and NCR-G3, two human EC cell lines studied (Kawabe et al 2013). 
EC cells which are considered malignant counterparts of ES cells have a limited capacity for 
differentiation (P.W.Andrews et al. 2005). Since we had observed unexpected difference in 
R-10G binding activity to riPSC clones we generated, investigating their differentiation ability 
became of great interest. We hypothesized the riPSC clones could vary in their capacity to 
differentiate. Our next aim was to investigate the differentiation ability of riPSC both in vitro and 
in vivo. 
For in vitro differentiation, cells were mildly dissociated and culture on low attachment dishes in 
riPS media without LIF and 2i. Cells were contained for 7 days during when they formed 
spherical aggregates with smooth boundaries. On day 7, we collected the aggregates and treated 
them with Accutase for mild dissociation. Cells were replated on gelatin coated dishes for 
spontaneous differentiation. Aggregates successfully attached to culture dishes and we observed 
morphological change in cell appearance at the outgrowths 
To evaluate differentiation, we fixed and stained differentiated riPSC against markers for three 
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germ layers; -Fetoprotein (AFP) (endoderm), Smooth muscle actin (SMA) (mesoderm) and ?
Tubulin (ectoderm). riPSC clones uniformly gave raise to cells of all three germ layers. 
Additionally, we isolated RNA samples and performed RT-PCR to detect expression of germ 
layer specific transcripts; GATA4, SOX17 (endoderm), Fetal liver kinase (flk) (mesoderm) and 
Neural cell adhesion molecule (Ncam) (endoderm). (data not shown) 
As Figure 12 shows riPSC successfully differentiated as confirmed by expression of germ layer 
specific proteins.  
In vivo differentiation 
Our next focus was to investigate the behavior of riPSC in vivo by performing teratoma assays.
Figure 12.riPSC in vitro differentiation. Dissociated riPSC formed embryoid bodies in 
suspension culture. Embryoid bodies were attached and differentiated into derivatives of three 
germ layers: -Feto protein (AFP), Smooth muscle actin (SMA), and ?Tubulin (Tuj1).   
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We subcutaneously injected 1×106 cells in the neck region of BALB/SCLC-ν/ν mice. Palpable 
masses developed in all the injected mice. We had set an endpoint for tumor size extraction at 
2cm diameter. We observed a difference in tumor mass growth rate, whereby tumor masses from 
riPSC#3 and riPSC#11 injection grew significantly, more rapidly in comparison to riPSC#6 
injected groups. We harvested these masses earlier in accordance to our endpoint. Mice were 
sacrificed and tumor masses harvested 3-5 weeks after injection. Tumor masses were fixed in 
4%PFA and then embedded in paraffin. Sections were cut and H&E staining performed. Tumors 
from riPSC#6 consisted of derivatives of all three germ layers in Figure 13: Glands and ciliated 
(endoderm); muscle fiber and cartilage (mesoderm); neural tissue and epidermis (ectoderm). On 
the other hand riPSC#11 and riPSC#3 derived masses consisted of undifferentiated cells and were 
identified as immature teratomas. 
Figure13. riPSC in vivo differentiation. Dissociated riPSC were injected into 
immunocompromised mice. A~F riPSC#6 derived teratoma consisted of endodermal glands 
and ciliated epithelium, mesodermal cartilage and muscle fiber, ectodermal neural tissues and 
epidermis. G and H riPSC#11 derived tumor consisting of undifferentiated cells. 
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Culture system for directed differentiation of riPSC toward a neuronal fate 
We first subjected riPSC to a differentiation protocol similar to that of P19 cells involving 
exposure to retinoic acid (RA). riPSC were dissociated in single cells using trypsin and then 
grown under floating conditions  for 4 days in DMEM/F12 media supplemented with 1%B27 
and 0.5M RA. During this period, spherical aggregates formed. These were trypsinized and 
replated on pol-l-lysine coated culture dishes. Cells were cultured further for 8 days in 
DMEM/F12 supplemented with 1%N2, 1%B27 and 0.5M RA. On day 12 the cells were fixed 
with 4%PFA and immunostained for the neuron marker ? tubulin. Results are shown in Figure 
14. While the cells appeared to be positive for ? tubulin, they had few axonal like projections 
that are typical of neurons. Moreover, the immunostaining had a high back ground. We attempted 
to expose riPSC to a modified protocol as well use different antibodies. 
Figure14. Directed differentiation of riPSC toward a neuronal fate. Immunocytochemical 
analysis of differentiated riPSC at day 12. Cell were positive for the neuronal marker  
?Tubulin (Tuj1) (red).  
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We modified and applied two protocols that at the time been reported to induce iPSCs to become 
neural lineage cells (Chang MY et al., 2010; Kikuchi T et al., 2011). A scheme of the method 
used is shown in Figure 15.  riPSC were dissociated into single cells using Accutase and 
allowed to form embryoid bodies in riPSC media without LIF and 2i for 7 days. EBs were mildly 
dissociated using Accutase and replated on gelatin coated dishes for an induction step. Culture 
media was changed to DMEM/F12 supplemented with 1%B27 and 1%N2. During this culture 
period, we observed morphological changes and cells acquired bipolar morphology typical of 
neural stem cells.  
We explored the identity of these cells by immunostaining for neural progenitor cell marker 
Nestin. As in Figure 15.B, we confirmed a large population of nestin positive cells. RT-PCR 
analysis also showed upregulation of nestin, pax6 and blbp in comparison to EB differentiation 
day 7. Furthermore early neuronal markers Ascl1, Satb2, Trb1 and NeuroD1 were also expressed 
confirming neuronal patterning.  
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Having confirmed the specified differentiation had been initiated, we subjected the cells to the 
last part of the differentiation protocol. For this the cells were replated onto poly-l-lysine coated 
dishes and exposure to 10ng/mL basic fibroblast growth fator (bFGF) and sonic hedgehog (Shh). 
After 5 days bFGF and Shh were withdrawn and cells treated with BDNF, GDNF, ascorbic acid 
and dbAMP for terminal differentiation. After 21 days of differentiation, cells were fixed with 
4%PFA and immunostained for neuron marker proteins ? Tubulin and Map2. Results are 
shown in Figure 16. The cells had acquired morphology typical of neurons and abundantly 
expressed ? Tubulin and Map2.  
We also attempted to characterize the type of neuron population. Differentiation had been 
Figure15. Directed differentiation of riPSC toward a neuronal fate. A. Schematic of 
differentiation protocol. B. Day 14 differentiated riPSC. Cells acquired bipolar morphology 
and were positive for Nestin (red). Nuclear stain Topro (blue). C. RT-PCR analysis of early 
neuronal markers at various stages of differentiation.  
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initiated with the mophogen, Shh which is known to direct differentiation to dopaminergic 
neurons (Cooper O et al. 2010; Hartfield EM et al. 2014). Therefore we immunostained day28 
riPSC derived neurons against tyrosine hydroxylase (TH), a marker for dopaminergic neurons. 
Neurons were identified as ? tubulin positive cells. We detected TH expressing cells albeit the 
population being much lower than we had anticipated. We resorted to isolating RNA and 
conducting RT-PCR analysis for transcripts of other neuron populations. RT-PCR analysis 
showed expression of dopaminergic genes TH and engraild (EN)-1 expression as well as 
N-methyl-D-aspartate receptor (NMDAR) subunits: GluN1, GluN2A and GluN2B, excitatory 
amino acid transpoter (EEAT)-3 and vesicular glutamate transporter (VGLUT)-2 that are typically 
expressed in excitatory glutamate neurons. We did not detect transcripts for glutamic acid 
decarboxylase (GAD)-67 (GABAnergic neurons), choline acetyltransferase (ChAT) (cholinergic 
neurons) or tryptophan hydroxylase (TPH) (serotonergic neurons) (Figure 16). Taken together, 
these findings indicated that riPSC had indeed differentiated into a neuron population that 
consisted of excitatory glutamate neurons and dopaminergic neurons. 
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Since we had observed differentiated neurons expressed genes typical of NMDA glutamate 
neurons, we next investigated whether the cells could respond to agonist stimulation. NMDAR 
stimulation evokes calcium ion infux. We examined calcium signaling following stimulation of 
differentiated neurons with NMDAR agonist NMDA.  
Cell were loaded with Fluo-3-AM at 37 °C , 5%CO2 for 1 hour. After washing cells were 
incubated in recording media (Material and methods) for 30 minutes. We then stimulated cells 
with 200M NMDA and observed Ca2+ transients for 10 minutes. NMDA application lead to an 
increase in Ca2+ levels in the cells. NMDA mediated Ca2+ influx was abolished with treatment by 
Figure16. Directed differentiation of riPSC toward a neuronal fate. Immunocytochemical 
analysis of riPSC derived neurons at day 28. Cell were positive for neuronal markers  
?Tubulin (Tuj1) (green) and Map2 (red). A population of tyrosine hydroxylase (TH) (red) 
cells was detected. RT-PCR analysis of neuron type markers.   
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the selective NMDA receptor antagonist,  
MK-801. Omission of extracellular Ca2+ with 10mM EGTA suppressed response to NMDA 
indicating the Ca2+ dynamics were as a result of Ca2+ influx.  
These results taken together indicate riPSC can be directed to differentiate into neurons that are 
reactive to agonist stimulation. 
Figure16. Fluo-3-AM Ca2+ imaging of day 25 riPSC derived neurons. Basal fluorescence of 
neurons without stimulation and 5 minutes after stimulation with 200M NMDA.     
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Discussion 
We describe generation of iPSC like cells from adult rat fibroblasts using a non viral multiprotein 
expression plasmid vector. We also characterized the cells with regard to pluripotency markers. 
riPSC clones differentially expressed the cell surface glycan epitope defined by R-10G antibody 
but expressed TRA-1-81 epitope similarly. R-10G highly reactive riPSC clone formed teratomas 
while low reactive clones resulted in tumors consisting of undifferentiated cells. All clones 
differentiated in a similar fashion in vitro. We differentiated riPSC into neurons consisting of 
glutamatergic and dopaminergic neurons.     
Yamanaka and his group established mouse iPS cells using multiple virus vectors and rat iPS 
cells have been generated using retroviral and lentiviral vectors (Liao J et al., 2009; Li W. et al., 
2009; Chang Y. et al., 2010; Liskovykh M. et al., 2011). When we embarked on this work, 
reports of rat iPSCs were few and the studies used lentiviral transduction to deliver transcription 
factors (Li W et al. 2009; Liao J et al 2009; Chang MY et al 2010). Viral approach has setbacks 
including genomic integration and persistence of transduced genes that can be reactivated during 
differentiation. Indeed, reactivation of c-myc resulted in tumor formation in iPS cell derived 
offspring (Okita et al, 2010). Methods have been developed to generate integration-free iPS cells 
including episomal vectors (Yu, J. et al, 2009), synthesized mRNA (Warren, L. et al, 2010), piggy 
Bac system (Woltjen, K. et al, 2009). In this work we successfully delivered a multiprotein 
expressing non-viral vector through nucleofection. Non-viral technique has only been reported 
for rat iPS cell generation by Merkl et al. (Merkl et al, 2013).  
At first we cultured generated colonies in riPSC media containing human LIF. Colonies however 
had rough edges unlike those of previous reports (Li W et al. 2009) suggesting LIF alone was 
insufficient in maintaining these cells in culture. Li et al. utilized LIF in combination with 
chemical inhibitors, CHIR99021 and PD035901 (2iL). Addition of 2i to our culture system 
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improved colony morphology and colonies acquired clear boundaries. Both rat ESC and rat iPSC 
studies have shown 2i are necessary for maintaining these cells n culture. 2i block differentiaton 
pathways by 1) blocking MAPK/ERK pathway 2) reducing GSK3 activity hence maintaining 
pluripotent state while leading differentiating cells to cell death (Ying et al. 2008). iPS cells are 
susceptible to sporadic differentiation and 2iL system reduces differentiation. Recently, Chen Y. 
et al reported unsolicited differentiation could be attributed to over inhibition of GSK3 and fine 
tuning of GSK3 inhibitor concentration increases stem cell maintenance in rat ES cells (Chen Y. 
et al, 2013). It is probable that this is the also the case with rat iPS cells and would be interesting 
to explore.      
Expression of pluripotency makers is paramount in identification and characterization of iPS cells. 
riPSC we generated expressed Nanog and SSEA1 proteins as well as various pluripotency 
marker transcripts. These results are in accordance with reports on rat ES and iPS cells from other 
groups mentioned above. Moreover, riSPC continued to express Nanog and SSEA-1 after 
multiple passaging. 
Methylation status of Oct3/4 promoter region were inconsistent with previous reports on rat iPS 
cells. Merkl et al. reported the region as being almost completely hypomethylated. The data 
discrepancy could be attributed to the type of vector used, difference in species of source cells or 
as a result of unsuccessful reprogramming. Unsuccessful reprograming is highly unlikely given 
we detected endogenous Nanog transcript expression as well as protein expression. Alternatively, 
it could be speculated that the first two demethylated sites in the Oct3/4 promoter region may be 
sufficient to express Oct3/4. Further studies are needed to clarify which demethylation site(s) are 
pivotal for Oct3/4 expression. 
Karyotypic abnormalities occur frequently in ES and iPS cells. Chromosomal instability is 
widely reported in mouse and human iPS cells (Laurent LC et al. 2011). Liskovykh et al. 
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reported high ratio of aneuploid and tetraploid cells in rat iPS cells they had generated. Our 
findings are in accord with this. Rate of karyotypic abnormalities is known to increase with 
increasing passages and culture duration. Prolonged passaging and growth in culture results to 
gain of chromosomes. Abnormalities may also occur during reprogramming process (Ben-David 
U and Benvisity N. 2011). Aneuploidy results in alteration in gene expression as well as 
alterations in cellular function and processes.  
We characterized riPSC with regard to a keratan sulfate glycan epitope defined by R-10G 
antibody. We observed unexpected differential expression of R-10G binding epitope while 
TRA-1-81 binding was similar.We had first aimed at exploring usefulness of R-10G as a new 
marker identifying rat iPS cells. Preliminary work in developing the antibody showed the 
antibody reacted with human ES and iPS cell lines. Although riPSC reacted with R-10G, it was 
surprising that aneuploidy clones had lower reactivity in comparison to normal karyotype clone. 
R-10G and TRA-1-81 epitopes are both keratan sulfate glycans, albeit of different structure, and 
share the carrier protein, podocalyxin (Kawabe K. et al 2013). It could be speculated that the 
difference in R-10G binding was as a result of a difference in carrier protein level expression 
rather than expression of R-10G binding epitope in riPSC clones. However this notion is 
improbable considering TRA-1-81 expression was comparable.Cell surface glycans are popular 
targets for not only identifying and characterizing pluripotent stem cells but also for exploring 
pluripotency, selfrenewal and differentiation. Glycan signatures vary with development stages 
and differentiation states. They are also distinct in cells types (Tateno H. et al., 2011). The 
reprogramming process is basically de-differentiation of somatic cells to a pluripotency after 
which cells express pluripotency markers that were initially unexpressed. In this light, it is 
probable that a sort of shift/alteration in glycan surface molecules occurs as cells acquire 
pluripotency. Indeed, somatic cells originally with distinct glycan profiles acquire glycan profiles 
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similar to ES cells upon induction to pluripotency (Tateno H. et al., 2011; Hasehira K. et al ., 
2012).  
In summary, we identified a unique glycophenotypic variation in riPSC clones. The correlation 
between karyotypic anomaly and observations on R10-G binding are also of great interest and 
remain to be elucidated. Out of the 11 clones that we picked and expanded, only three had been 
successfully maintained in culture. This limited the number of clones we analyzed. Analysis of 
more clones, especially those of normal karyotype to further draw clear conclusions on the 
observations is necessary.     
We explored differentiation potential of riPSC. We applied EB formation system accompanied by 
mono layer culture. In vitro differentiation of ES and iPS cells is normally initiated though EB 
formation during which stem cell state is lost and differentiation initiated. Further culture of EBs 
in adherent conditions enables cells to differentiate and mature. riPSC were able to form EBs 
which differentiated into endoderm (AFP positive), mesoderm (SMA) and ectoderm (?
Tubulin) lineages. This is in accordance with previous studies on rat ES and iPS cells.     
In our system suspension culture of riPSC was carried out iPS media (containing 15% FBS) 
without 2iL resulting in aggregate formation. This was in disagreement with Merkl et al. who 
also generated rat iPS cells using a non viral vector. They reported rat iPS cells cultured in 
suspension in medium containing serum died after two days and did not form EBs. Their system 
additionally required GSK3inhibition for successful EB formation (Merkl et al. 2013). However, 
our findings are in agreement with Chang et al who generated EBs from rat iPS cells in serum 
containing media similar to ours (Chang MY et al, 2010). These observations suggest that fine 
differences in nature of rat iPS cell lines exist that may in turn affect optimal culture conditions 
and processes. riPSC clones not only formed EBs similarly but also differentiated into three germ 
layers derivatives. We did not observe any differences that could distinguish clones during 
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differentiation culture.  
riPSC could form tumor masses when injected into immunocompromised mice. Tumor masses 
from R-10G highly reactive clones were identified as teratomas. riPSC clones with low reactivity 
to R-10G formed tumors made up of undifferentiated cells. Teratoma assay is considered a gold 
standard to analyze pluripotency of pluripotent cells especially during establishment of new cell 
lines (Gertow et al. 2007; Wesselschmidt 2011). Teratomas are benign tumors made up of 
differentiated cells from all three germ layers. The assay involves injection of cells into 
immune-compromised mice, whereby they proliferate and differentiate forming tumors. Tumors 
are extracted and subjected to histopathological analysis to verify nature of the cells comprising 
the tumor. Pluripotency and tumorigenecity are closely related phenomena (Knoepfter, 2009; 
Andrew S. Lee et al, 2013). In this light, teratoma assay serves as a potent test not only for 
pluripotency but also a test for tumorigenecity.   
riPSC#6 resulted in teratomas consisting of cells of all three germ layers confirming trilineage 
commitment in vivo. Tumors formed by clones with low R-10G reactivity had more rapid growth 
and were harvested earlier. The aggressive growth rate couple with the poorly differentiated 
nature is suggestive of a tumorigenic nature although further analysis are necessary to elucidate 
this possibility. The reason of these clones did not form mature teratomas is unclear. However, 
karyotypic abnormality can be speculated. 
As previously discussed, R-10G reacts to human ES and iPS cells with almost no reactivity to 
human EC cell lines. EC cells are tumorigenic and result in malignancies. In this light, it is 
reasonable to consider that a difference in R-10G glycan epitope profile of teratoma and 
non-teratoma forming riPSC exists. Fujitani et al. in their work reported cellular glycomes to be 
highly cell type specific and suggested the presence of stem-cell specific glycosylation spectra 
(Fujitani N. et al 2013). Epitopes defined by R-10G could provide a useful tool to investigate 
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glycan dynamics surrounding pluripotency and tumor formation.       
We also determined riPSC could be directed to differentiate into neural lineage cells. riPSC 
underwent a step wise acquisition of neuropotency, morphological changes and expressed 
markers for observed in authentic neural progenitors and neurons. Chang et al. reported 
derivation of neurons from rat iPS cells (Chang MY et al .,2010). In this study 10% of neuron 
population was identified as dopaminergic. However, the remaining population was no defined. 
We identified excitatory glutamatergic neurons alongside a population of dopaminergic neurons. 
Other neuronal types were not identified, by RT-PCR at least. Although differentiation was done 
using morphogens, Shh and FGF-8, which drive dopaminergic neuron differentiation, only a 
small population of TH+/Tuj1+ cells was detected. Neural differentiation using same morphogens 
on human iPS cells yield about 80% TH positive neurons (Kikuchi T. et al, 2011). This suggests a 
difference in response to morphogenic stimulation in rat and human iPS cells. Neurons 
differentiated from riPSC could be used to study pharmacological glutamate neurotransmitter 
signaling.  
In summary, we demonstrated that iPS cells can be generated from adult rat fibroblasts using a 
non viral plasmid vector. riPSC generated have ES cell morphology and expresses pluripotency 
markers. Expression of a keratan sulfate glycan epitope defined by R-10G antibody varied in 
riPSC clones. Teratoma formation assay showed a clone highly reactive to R-10G formed 
teratomas while low reactive clones results in tumors consisting of undifferentiated cells. This 
glycophenotypic difference may potentially be useful in evaluating rat iPS cells as well as 
studying the role of glycans in pluripotnecy and carcinogenesis. riPSC could be differentiated 
into a neuronal lineage that can be applied in the study of neurogenesis and neuron functions.  
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PART 2: Selective HDAC8 inhibition in pluripotent P19 cells.   
INTRODUCTION 
Histone acetylation and deacetylation are epigenetic processes that regulate gene expression and 
in turn cellular functions (Shahbazian MD and Grunstein M, 2007; Haberland M. et al.,2009). 
Histone acetyl tranferases (HATs) transfer acetyl groups to lysine residues on histones causing 
chromatin structure to relax due to reduced interaction of DNA and histones. Histone 
deacetylases (HDACs) are a group of enzymes that are responsible for deacetylation of lysine 
residues on histones and non-histone proteins. Deacetylation of histones alters chromatin 
structure thus regulating downstream gene expression and in turn various other cellular processes. 
HDAC isoforms are classified into four classes; Class?(HDAC 1,2,3 and 8) which are 
homologous to yeast RPD3, Class? (HDAC4-7,9and10) which are homologous to yeast Hda1 , 
Class?(Sirt1-7) and Class?(HDAC11) (de Ruijter AJ. et al., 2003; Gregoretti IV et al., 2004). 
HDAC inhibition has extensively been reported to suppress proliferation and alter differentiation 
in tumor cells. Indeed, HDAC inhibitors (HDACi) are clinically used in cancer management 
(vorinostat). Application of HDACi in nonmalignant diseases is also of interest. Disconcerted 
acetylation homeostasis alongside increase in HDAC activity in neurodegenerative disorders is 
widely reported (Saha RN. et al., 2006; Kwok JB. 2010) and HDAC inhibition has been shown to 
mediate neurogenerative and neuroprotective properties in neurological conditions such 
Alzheimers disease, Huntingtons disease, stroke and Parkinsons disease (Fischer A et al., 2007; 
Chuang DM. et al. 2009). However, reports on effects of HDAC inhibition in the brain and in 
neurodegenerative conditions are contradictory. Individual HDAC isoforms function 
neuroprotectively alleviating neurological conditions (Mac C.et al., 2011) or result in 
neurotoxicity (Bardai FH. et al., 2011). Intriguingly, some HDAC isoforms function in a 
differential manner exerting both protective and toxic effects (Bardai FH. et al., 2012). This 
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contraction could be attributed to the non-selectivity nature of the inhibitors used as majority of 
HDACi available are poorly selective and target multiple HDAC isoforms. Therefore studies 
using isoform-selective inhibitors should be useful in understanding contribution of individual 
HDAC isoforms in the nervous system as well as providing potential therapeutic agents devoid of 
undesirable effects.  
Additionally, there are reports showing epigenetic modification via HDAC inhibition improves 
reprogramming efficiency and promote iPS cell generation (Huangfu D. et al., 2008; Mali P. et 
al., 2010). In this light, HDACi can be useful in modulating differentiation processes.  
HDAC8 is a unique member of the class 1 HDACs. HDAC8 shares only 43% sequence identity 
with other members of its class as well as a shorter C terminal (Buggy JJ et al., 2000; Bolden JE 
et al.,2006). Moreover, HDAC8 has a unique expression pattern and is abundantly expressed in 
the brain, kidney and prostate (Hu E et al,.2000). HDAC8 has been implicated in with a number 
of diseases including neuroblastoma (Oehme I et al.,2009) and Cornelia de Lange syndrome 
(Deardorff MA et al., 2012). Importance of HDAC8 is mostly associated with tumor cell 
proliferation and its knock down inhibits growth (Hu E et al,.2000). However, little is known 
about the role of HDAC8 during development and differentiation.      
HDAC8 high expression in neuroblastoma and its association with poor prognosis (Oehme I et 
al.,2009) lead us to hypothesize that HDAC8 inhibition might regulate neurogenesis. In this study, 
we investigated involvement of HDAC8 inhibition on embryonic neurogenesis using retinoic 
acid treated P19 cells as a model for neural progenitor cells and a HDAC8 selective inhibitor 
(Suzuki T. et al. 2012). P19 cells are pluripotent cells that can be induced to differentiate to 
various cells by aggregation and induction by drugs. P19 cells induced with retinoic acid (RA) 
under floating culture conditions form embryoid body like aggregates that differentiate into 
neural lineage cells (Mc Burney MW. et al., 1983).  
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RESULTS 
Class1 HDAC isoform expression in RA treated P19 cells                         
Firstly, we examined the expression of the Class1 HDACs HDAC 1, 2, 3, and 8 in 
undifferentiated and RA treated P19 cells. As shown in Figure 1, all Class 1 HDACs were 
uniformly expressed in P19 cells before and after induction with RA.  
Next, we investigated whether histone 4 (H4) acetylation level was modulated by HDAC8 
inhibition. Cells were treated with vehicle (DMSO) or 25M HDAC8 inhibitor for 48 hours and 
Figure 1. A. Expression of class?HDAC isoforms. P19 cells treated with RA in non-adherent 
conditions for 4 days. RT-PCR analysis of 0 day, day4 control and HDAC8i treated embryoid 
bodies (EB). B. Histone4 acetylation. Western blot analysis of P19 cells treated with RA in 
non-adherent conditions for 48 hours treated HDAC8i. Actin is loading control. 
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protein samples collected. Western blotting results showed an increase in acetylated Histone 4 
(AcH4) levels in inhibitor treated cells in comparison to control (Figure 1B).  
HDAC8 inhibition decreases size of RA treated P19 cell aggregates 
It has been widely reported that pan-HDAC inhibitors such as the aliphatic acids, valproic acid 
(VPA) and sodium butyrate; hydoxamates, vorinostat (SAHA) and trichostatin A (TSA) result in 
cell cycle arrest, decrease in proliferation and induce apoptosis in a cell specific manner 
(Dokmanovic M. et al., 2007). We investigated the effect of HDAC8 specific inhibition on 
proliferation and cell survival of RA treated P19 cells. P19 cells cultured in non-adherent 
conditions form round clustered aggregates consisting of proliferating cells.  
P19 cells were treated with RA with and without HDAC8 inhibitor at various concentrations. 
HDAC8 inhibition resulted in distinct reduced aggregate formation in a dose dependent manner 
(Figure.2A). At 10M HDAC8i, we observed both large and small aggregates while at higher 
concentrations small aggregates were most apparent. Quantitative analysis of total aggregate area 
was conducted and results were shown in Figure 2B. Difference in cell proliferation was further 
evaluated via measurement of 
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-8) 
reducing activity. WST-8 reducing activity was lower in HDAC8i treated cells in comparison 
with control (Figure.2C).
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HDAC inhibition has been reported to induce apoptosis (Tang X. et al., 2004). It could be 
postulated that HDAC8i treatment reduced aggregate size as a result of a toxic effect that in turn 
resulted in increase of cell death. Consequently, we evaluated the extent of cell death in control 
and HDAC8i treated cells. Cell death was evaluated via analysis of DNA fragmentation in 
genomic DNA isolated from aggregates after 4 days of culture. No significant difference in DNA 
fragmentation was seen between untreated and HDAC8i treated cells (Figure 2D). Collectively, 
these results demonstrate HDAC8 inhibition reduces cell proliferation without inducing apoptotic 
cell death in RA induced P19 aggregates. 
Figure 2. Concentration dependent suppression of proliferation by HDAC8 inhibition. P19 
cells treated with HDAC8i in the presence of RA in non-adherent conditions for 4 days. A. 
Phase contrast images of aggregates. B. Area of aggregates at culture day 4. C. Cell viability 
determined by WST-8 assay.  D. DNA fragmentation analysis. Lane 1: Control, Lane 2: 
HDAC8i 25?M, Lane3: RA 100?M as DNA fragmentation positive control.
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Expression changes in cell cycle related and neural differentiation specific genes after 
HDAC8i treatment 
In the light of the proliferation suppressing effects observed, we sort to elucidate on the effect of 
HDAC8 inhibition on expression of cell cycle associated genes. RT-PCR analysis showed an up 
regulation of cyclin dependent kinase inhibitor 1A (p21) mRNA expression in HDAC8i treated 
cells. On the other hand, HDAC8 inhibition did not result in significant differences cyclin D1 and 
Ki67 mRNA expression levels. We also examined transcription of Musashi-1 which contributes 
to maintenance of neural precursor cells and is a marker of these cells. RT-PCR analysis showed 
HDAC8 inhibition induced a reduction of Musashi-1 expression. Constant with this finding, 
protein level of Sox2 which functions to maintain neural precursor cells in their progenitor state,  
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was decreased in inhibitor treated cells (Figure.3C). Thus taken together, these data suggest 
HDAC8 inhibition suppresses cell proliferation and undifferentiated state of RA treated P19 
cells.   
During the process of neurogenesis, self-renewal of progenitor cells and the switch to neuronal 
differentiation is controlled by the balance in 1) expression of repressor bHLH factors such as 
Hes1 and Hes5, which regulate and maintain undifferentiated state, and 2) proneural bHLH 
factors such as Math, Ascl1, NeuroD, which positively promote cell cycle exit for differentiation. 
Self-renewing NPCs convert into mitotically inactive cells that later differentiate into mature 
neuronal lineage cells including neurons, astrocytes and oligodendrocytes. Given that HDAC8 
inhibition exerted an anti-mitotic effect associated with a decrease in factors contributing to 
maintaince of progenitor state, we sort to investigate whether expression of bHLH factors was 
Figure 3. Expression of cell cycle regulators, pluripotency markers and bHLH factors. P19 
cells treated with HDAC8i in the presence of RA in non-adherent conditions for 4 days. 
mRNA and protein were isolated at day 4.  A. RT-PCR analysis for mRNA expression.  B. 
Quantitative data of RT-PCR results (mean of 4 independent experiments). C. Western blot 
analysis for Sox2. Actin is loading control. 
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affected. RT-PCR analysis showed a decrease in expression of the repressor bHLH factor, Hes 5 
following HDAC8 inhibition. Contrastingly, Hes 1 mRNA expression levels was not changed.  
Given cell-cycle exit is coupled with initiation of differentiation, we analyzed whether HDAC8 
inhibition during proliferation would affect expression of proneural bHLH factors. Expression of 
Neuorogenin1 (Ngn 1), Neurogenin 2 (Ngn 2), NeuroD1 were assessed by real-time PCR. We did 
not observe any significant alterations in transcript expressions of these genes (Figure 3B). 
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DISCUSSION 
HDAC8 remains the least studied class ? isoform in regard to neurogenesis and 
neurodegenerative conditions. We used RA treated P19 cells, a well-established model of neural 
precursor cells, to investigate effect of HDAC8 specific inhibition during neurogenesis. Firstly, 
treatment with HDAC8i resulted in robust inhibition of cell proliferation without causing cell 
death. Inhibition of cell proliferation was characterized by upregulation of p21 expression. 
Increase of p21 expression is associated with cell cycle arrest in G1 phase (Ocker M.et al.,2007). 
In this light, inhibition of cell proliferation we observed could be attributed to cell cycle arrest in 
G1 phase, at least in part. As we only analyzed cyclin D1 transcript expression, which was 
unaffected by HDAC8 inhibition. Further analysis of other cyclins is needed evaluate their 
possible involvement. 
Secondly, our findings demonstrate HDAC8i treatment resulted in decrease in Sox2 protein 
levels. Sox2 is involved in maintenance of progenitor state in neural precursor cells. Effect of 
HDAC inhibition on Sox2 expression appears to vary in cell types. Zhou Q. et al. reported broad 
class?and class?HDAC inhibitors down regulated Sox2 expression in adult mouse neural stem 
cells (Zhou Q. et al. 2011). Contrastingly, Sox2 was negatively regulated by HDAC2 in 
experiments using conditional gene deleted neuroblasts (Jawerka M. et al.,2010). In 
oligodendrocyte precursor cells, inhibition of HDAC activity upregulated genes that maintain 
neural stem cell state including Sox2 (Lyssiotis CA. et al., 2007). HDAC regulation of Sox2 
expression is probably cell type specific and dependent on the HDAC isoform inhibited.  
We also found that HDAC8 inhibition downregulated Musashi-1 expression. This is in agreement 
with our data showing downregulation of Sox2 as Musashi-1 functions to maintain 
undifferentiated state of neural progenitor cells. Musashi-1 is an RNA-binding protein associated 
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with maintenance and cell division of neural progenitor cells (Okano H. et al.,2005). Furthermore, 
Musashi-1 is a translational repressor of p21 and regulates the Notch-1 signaling pathway that in 
turn alters cell cycle progression (Okano H. et al.,2005). Consistent with our findings, Oehma I. 
et al. reported down regulation of nestin (a marker for neural progenitor cells) in HDAC8 knock 
down neuroblastoma cells (Oehma I. et al., 2009). Taken together findings suggest HDAC8 
inhibition is involved in suppression of progenitor and undifferentiated state.  
Furthermore, we observed suppression of the repressor bHLH factor Hes5 mRNA expression. 
However, Hes1 and proneural bHLH factors examined were not altered by HDAC8 inhibition. 
Hes factors are effectors for notch signaling pathway and functionally antagonize proneural 
bHLH genes including Mash1, Math1 and Neurogenin hence preventing differentiation (Ohtsuka 
T. et al., 2001; Kageyama R et al.2005). Notch signaling plays an important role in neural 
development, cell proliferation and differentiation (Miele and Osborne, 1999; Kageyama R et 
al.2008). Notch mediated cell-cell interaction is essential for maintenance of dividing cells and 
its activation inhibits cellular differentiation. Hes5 downregulation could be speculated to be as a 
result of epigenetic modulation of complexes as the promoter or because of alteration of Notch 
signaling pathway by other genes such as Sox2 and Musashi-1. Tiberi L. et al. reported epigenetic 
silencing of Hes5 through the recruitment of the NAD+ - dependent deacetylase, Sirt1, to Hes5 
promoter (Tiberi L. et al., 2012). Although, of a different type, this study suggests regulation of 
Hes5 expression through epigenetic mechanisms.  
As previously described, downregulation of repressor bHLH factors is concomitant with 
proneural bHLH factor activation driving differentiation. NeuroD1, Ngn1 and Ngn2 were 
unaffected by HDAC8 inhibition. However, we did not exhaustively analyze proneural bHLH 
factors and it is not possible to draw conclusions on whether HDAC8 inhibition effect on 
proneural genes from the present data. Valproic acid (VPA) a pan-inhibitor, has been reported to 
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up-regulate NeuroD1 in adult neural progenitor cells (Hsieh J. et al.,2004). In contrast to this, Yu 
IT. et al. reported up-regulation of Ngn1 and Math1 but not NeuroD1 following VPA treatment in 
embryonic neural progenitor cells (Yu IT. et al. 2009). Broad class?and ??HDAC inhibitors 
suberoylanilide hydroxamic acid (SAHA) and sodium butyrate (NaB) upregulated NeuroD1 and 
Ngn1 in adult subventricular cells (Zhou Q. et al., 2011). This implies HDAC inhibition indeed 
upregulates proneural bHLH factors. However, certain differences in molecular mechanism 
responses such as cell type may exist.  
In summary, HDAC8 specific inhibition reduced proliferation in undifferentiated RA induced 
P19 cells. Restriction of proliferation was characterized by gene and protein expression changes 
demonstrating G1 arrest concomitant with suppression of undifferentiated progenitor state.  
Mechanisms through which HDAC8 inhibition is resulted in our observations, the causal steps 
and precise order of events leading to alterations in proliferation are crucial points that need to be 
determined through further studies. HDAC8 inhibition could alter expression of genes that 
mediate notch signaling such as Sox2 and Musashi-1, impacting downstream regulatory systems.  
Alternatively, HDAC8 inhibition may directly regulate Hes5 transcription. Chromatin 
immunoprecipitation (ChiP) and promoter assays on the Hes5 promoter should elucidate on this. 
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CONCLUSION 
In part 1, we generated rat iPS cells using a non-viral plasmid vector. The cells expressed 
hallmark pluripotency marker mRNA and proteins and differentiated to cells of three germ layer 
in vitro. We found a difference in glycophenotype among riPSC with regard to keratan sulfate 
glycan epitope that binds R-10G antibody. riPSC clone highly reactive to R-10G formed 
teratomas consisting of derivatives from three germ layers. Clones with low reactivity formed 
tumor masses made up of undifferentiated cells. This difference in glycophenotype could be 
useful to evaluate and study the role of glycans in pluripotency and tumorigenesis. riPSC were 
also differentiated to neurons using a multistep protocol and resulting cells consisted of 
glutamatergic and dopaminergic neurons. Glutamatergic neurons responded to agonist 
stimulation. riPSC can serve as a source for neurons for pharmacological and toxicological 
studies as well as a model to study neurogenesis process. 
In part 2, we explored the effect of HDAC8 inhibition on neurogenesis using P19 cells a model. 
HDAC8 was expressed in retinoic acid induced P19 cells and inhibition suppressed proliferation 
without inducing cell death. Upregulation of p21 suggests G1 cell cycle arrest. We found HDAC8 
inhibition resulted in decrease in Sox2 protein, Musashi-1 and Hes5 mRNA expressions implying 
a change in undifferentiated state. The findings in this part of the thesis uncover as well as 
suggest a role for HDAC8 inhibition in neurogenesis.  
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Materials and Methods 
Animal experimental procedures were carried out in accordance with the guidelines and laws of 
the Japanese government and were approved by the Animal Care Committee of Ritsumeikan 
University. 
Cell culture
6 week male wistar rats were sacrificed ethically. Abdomens were sterilized and excess hairs 
shaved off. Skin specimens were dissected and washed twice in phosphate buffered saline (PBS). 
Skin specimens were grown on tissue culture dishes in Fibroblast media (Dulbeccos Modified 
Eagles Medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 100U/mL 
penicillin, 100g/mL streptomycin). Skin specimens were removed after 7 days and cells that 
migrated out of the skin pieces grown to confluence. Fibroblasts were passaged and used for 
reprogramming between passage 2 and 4.    
Mouse Embryonic Fibroblasts (MEFs) were maintained in Fibroblast media. For feeder layer 
preparation, MEFs were grown to confluence and inactivated by incubation with mitomycin C at 
37°C 5%CO2 for 3hours. MEFs were washed thrice with PBS and used for iPSC culture. 
rat iPS cells (riPSC) were cultured in riPSC media: high Glucose DMEM supplemented with 
15% FBS, 1mM -mercapto-ethanol, 1× nonessential amino acids , 100U/mL penicillin, 
100g/mL streptomycin, 1000U/mL leukemia inhibitory factor (LIF) supplemented with signal 
inhibitors 2i including MEK1/2 inhibitor PD 0325901 (0.5M) and GSK3 inhibitor CHIR99021 
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(3M) on inactivated MEFs. Media was renewed daily. Subsequent passage was done using 
trypsin-based dissociation with a split ratio of 1:4 every 4 to 5 days. 
Reprogramming 
Reprogramming was conducted using pCAG2LMKOSimO vector (kindly donated by Dr. K.  
Kaji, University of Edinburgh). 8g of pCAG2LMKOSimOvector was introduced into 106 
fibroblasts with the Basic Nucleofector Kit for Primary Mammalian Fibroblasts using the 
Nucleofector ?(Lonza) device (program V-013) and plated on inactivated MEFs. Cells were 
maintained in riPSC media. 400g/mL G418 was added for selection. Colonies were visible from 
day 7 post nucleofection and were picked at day 14-20. Individual colonies were transferred to 96 
well plates and dissociated with 30L trypsin. 70L riPSC media was added and cells transferred 
to 24 well plates with MEF feeder layer. Colonies were subsequently expanded. 
. 
In vitro differentiation of riPS 
riPSC were dissociated with 0.25% trypsin/EDTA and transferred to non-adherent bacterial 
culture dishes in riPSC media without LIF and 2i for embryoid body (EB) formation. On day7, 
EBs were dissociated with Accutase, attached on gelatin-coated tissue culture dishes and 
maintained in fibroblast media for an additional 7 days. Media was renewed every 2 days.   
Differentiation of riPS into Neurons 
riPSC colonies were dissociated and plated on non-adherent bacterial culture dishes in riPS 
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media without LIF and 2i with media change every 3 days. After 7 days EBs were collected by 
centrifugation and dissociated with Accutase. For induction of differentiation toward neuronal 
lineage, cells were plated on gelatin-coated tissue culture dishes and maintained in Induction 
media: DMEM-F12 supplemented with 100U/mL penicillin, 100g/mL streptomycin, 1% N2 and 
1% B27. At culture day 7 cells were dissociated using Accutase and plated on poly-l-lysine 
coated dishes in Induction media containing 10ng/mL basic fibroblast growth factor (bFGF) and 
cultured for an additional 5 days after which 100ng/mL FGF8 and 200ng/mL Sonic Hedgehog 
(SHH) were added. Media was changed to Induction media supplemented with 2% B27, 
30ng/mL brain derived neurotrophic factor (BDNF), 50ng/mL glia derived neurotrophic factor 
(GDNF) and 200nM ascorbic acid for terminal differentiation. 
Alkaline phosphatase staining and immunocytochemistry 
Alkaline phosphatase staining was performed using the Alkaline Phosphatase Detection Kit 
(Millipore, USA) according to the manufacturers recommendation.  
For immunocytochemistry, cells were fixed using 4% paraformaldehyde for 15 minutes at room 
temperature. Cells were then washed with PBS followed by permeabilization with 0.2% Triton 
X-100 in PBS for 15 minutes at room temperature. For R-10G immunocytochemical analysis 
cells were not treated with Triton X-100. Blocking was done with 3% FBS for 1 hour at room 
temperature. Primary antibody reactions were done overnight at 4°C. After washing with PBS, 
the cells were incubated with the respective secondary antibodies for one hour at room 
temperature. Cell nuclei were stained using ToPro 3 or DAPI. Cells were imaged with the 
confocal or fluorescence microscopes.  
Primary antibodies used: Nanog (1:500, Abcam), SSEA1 (1:500, Abcam), R-10G (1:100), Nestin 
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(1:500, Sigma), Smooth actin muscle SMA (1:250), Albumin (1: 250), Class ?- Tubulin 
(1:1000, Millipore), Map2 (1:1000 Sigma), Alexa fluorophores 488 and 555 were used for the 
respective primary antibodies at 1000 times dilution. 
Reverse Transcription-Polymerase Chain Reaction 
Total RNA was extracted using Sepazol and treated with DNase?to remove genomic DNA. 1g 
RNA was used for cDNA generation using the SuperScript ?First-Strand Synthesis System for 
RT-PCR as per the manufacturers protocol. PCR was performed using Onetaq DNA polymerase. 
PCR primers used are shown on Table 1. PCR products were resolved on 1.5% agarose gels and 
visualized by ethidium bromide staining. 
Genes Forward Reverse 
Nanog aagcagaagatgcggactgt aggccgttgctagtcttcaa 
Oct3/4 cgaggcctttccctctgttcct tctctttgtctacctcccttccttgc 
Sox2 ggccattaacggcacactgcc ttactctcctcttttgcacccctc 
Eras gctgcccctcagccgactgctact cactgccttgtactccggtagctg 
Lin28 cgggaggaggaagaagagatccac ccactctgcggattgatgcct 
Lefty tgaccatcaggtggccatttctg tgttgggcaggctgaccacttg 
Fgf4 tgtggtgagcatcttcggagtgg ccttcttggtccgcccgttctta 
Nodal gagcgtgtttggatggagagg atgccaacactttcctgcttgac 
Esg1 tccagaagtattccaggtcca ctccagggtcttcatggatt 
Nestin agccattgtggtctactga tgcaactctgccttatcc 
Ascl1 acccccttagccagaggaa gctgggtgtctggtttgttt 
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Satb2 tcttctgtgtggtggagcag ggggcgtctgtcacataact 
NeuroD1 acagctcccatgtcttccac aagattgatccgtggctttg 
Pax6 agttcttcgcaacctggcta ttgagcctcatccggagtctt 
Blbp ccagctgggagaagagtttg taacagcgaacagcaacgac 
Tbr1 gatgctcccttgttgttggt tcccaatcactggaggtttc 
VGluT1 tactggagaagcggcaggaagg ccagaaaaagcaatgtatgagg 
EAAT3 caaaatcgtgggcctgtact cccagcgattaggaacaaaa 
GluN1 ctcatctctagccaggtcta tcgcatcatctcaaaccagac 
GluN2A actccacactgcccatgaac ttgttccccaagagtttgctt 
GluN2B gtttgatgaaatcgagctggc tccagttcctgcagggagtt 
En 1 cctactcatggcttcggcta tagcggtttgcctggaac 
Th cagggctgctgtcttcctac gggctgtccagtacgtcaat 
ChaT tcattaatttccgccgtctc ccggttggtggagtctttta 
TPH cctttgcaagcaagaaggtc gcatcttggaaggtggtgat 
Table 1 
Bisulfite genomic sequencing 
Genomic DNA for bisulfite sequencing was isolated using the PureGene Genomic DNA isolation 
kit and bisulfite treatment was performed using Methyl Easy Xceed (human genetic signatures) 
following the respective manufacturers protocols. Oct3/4 promoter region was amplified using 
ExTaq HS DNA Polymerase. Primers are listed below (Table 2). PCR products were cloned into 
pGMTEasy (Promega) vector and sequenced with M13 forward primer.  
Genes  Forward Reverse 
Oct3/4 caatgggatcctggaggatcctcag agctctgaggtgtccagggcactat 
47 
attaagtattgggttagtaatgg taaccctaaacaactactcaacc 
 atgggattttggaggatttttag ctcaaacccaaatacccctactt 
Table 2
Karyotyping 
riPSC were treated with 10g/mL Colcemid for 3 hours. Cells were trypsinized into a single cell 
suspension and incubated in 0.075M KCl at 37°C for 15 minutes followed by fixation with ice 
cold methanol/acetic acid (3:1). Metaphase preparation and chromosome counting were then 
performed. 100 clones were analyzed for each clone. 
Teratoma formation Assay 
Animals were purchased from (Japan SLC, Inc). riPSC were typsinized, counted and injected 
subcutaneously into the neck region of BALB/cSLC-n/nmice. Tissue masses were harvested after 
3-5 weeks, fixed in 4% Paraformaldehyde and sectioned. Sections were stained with hematoxylin 
and eosin (H&E) according to standard protocols.
Calcium Influx 
For Ca2+ influx experiments, riPS derived neurons were cultured in poly-L-lysine coated 3.5 cm 
glass bottom dishes. Neurons were washed once with recording medium (RM): 129 mM NaCl, 
4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 4.2 mM glucose and 10 mM HEPES (pH 7.4), then 
incubated for 1 h at 37 °C in RM containing 30 nM Pluronic F-127 (Invitrogen) and 1.5 M 
fluo-3 acetoxymethyl ester. Culture dishes were then triple washed with Mg2+-free RM and 
induced fluo-3 Ca2+ influx activity visualized at 488 nm with confocal microscope. 
N-methyl-D-aspartic Acid (NMDA) was added directly onto the medium of the dish undergoing 
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microscopy to a final concentration of 200M. 
P19 Cell culture and differentiation 
Mouse embryonal carcinoma P19 cells were routinely cultured in alpha minimal essential media 
(?MEM) supplemented with 10% fetal bovine serum (FBS) (Gibco, USA). For differentiation 
into neural lineage , undifferentiated P19 cells were passaged twice then cultured in low adhesion 
culture dishes in the presence of 0.5?M all trans retinoic acid (ATRA) for 4 days under floating 
conditions. Cell aggregates formed were dispersed using Accutase, plated onto tissue 
culture-grade dishes coated with poly-L-lysine for and cultured for 5 days in the absence of 
ATRA. Cells incubated in a humidified atmosphere containing 5% CO2 at 37?C at all times and 
media renewed routinely every 2 days. 
RNA isolation and RT-PCR 
Total RNA was extracted using Sepazol and genomic DNA removed using DNase 1. 2?g RNA 
was reverse transcribed into cDNA using SuperScript ?? First-Strand Synthesis System for 
RT-PCR (Invitrogen). cDNA was amplified with THUNDERBIRD SYBR qPCR Mix on a ABI 
7500 real time PCR system Samples were run in triplicate and normalized against GAPDH. For 
semi-quantitative PCR cDNA was amplified using ExTaq. Primers used are shown below. 
Genes Forward Reverse 
Hdac1 ctgtccggtatttgatggct cacgaactccacacattgg 
Hdac2 ggcggcaagaagaaagtgtgc ggcatcatgtagttcctccagc 
Hdac3 tctgaggactacatcgactcc gtcgccatcatagaaatattg 
Hdac8 aacacggctcgatgctgg ccagctgccacttgatgc 
49 
Hes1 cggaatcccctgtctacctct ttggaatgccgggagctatc 
Hes5 gaaaaaccgactgcggaagc cgaaggctttgctgtgtttca 
Musashi1 gaggactcagttggcagacc tctgtgcctgttggtggttt 
CyclinD1 cacaacttctcggcagtcaa agtgcgtgcagaaggagatt 
p21 gcagatccacagcgatatcc acaccagagtgcaagacagc 
NeuroD1 tctgcctcgtgttcctcgt atgaccaaatcatacagcgagag 
Ngn1 ccagcgacactgagtcctg cgggcataggtgaagtctt 
Ngn2 aactccacgtccccatacag gaggcgcataacgatgcttct 
Gapdh(real time) tgcgacttcaacagcaactc tgcgacttcaacagcaactc 
Table 3 
Western blotting 
Total protein was extracted from cells using RIPA buffer and lysates centrifuged at 10K?g for 10 
minutes at 4?C. Protein samples (10-20 ?g) were resolved in 10 or 15% SDS-PAGE gels and 
transferred to PVDF membranes. Membranes were blocked for 1 h at room temperature and 
incubated overnight at 4°C with the respective antibodies, followed by application of horseradish 
peroxidase conjugated secondary antibodies. Proteins were visualized using the 
chemiluminescent substrate kit and Lumino-Image Analyzer, Las 4000.  
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